Transductional efficacy and safety of an intraperitoneally delivered adenovirus encoding an anti-erbB-2 intracellular single-chain antibody for ovarian cancer gene therapy

Gynecologic Oncology

Volumn 64, Issue 3, 1997, Pages 378-385

  Deshane, Jessy ^a   Siegal, Gene P ^a   Wang, Minghui ^a   Wright, Marci ^a   Bucy, R Pat ^a   Alvarez, Ronald D ^a   Curiel, David T ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ONCOPROTEIN; VIRUS VECTOR;

ADENOVIRUS; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; CONTROLLED STUDY; FEMALE; GENE THERAPY; HUMAN; HUMAN CELL; IN SITU HYBRIDIZATION; MOUSE; NONHUMAN; ONCOGENE NEU; OVARY CANCER; PERITONEUM; PRIORITY JOURNAL; SCID MOUSE;

EID: 0031104742     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1996.4566     Document Type: Article

References (39)

1. 1. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, Press MF: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707-713, 1989
2. 2. Hung M-C, Zhang X, Yan D-H, Zhang H-Z, He G-P, Zhang T-Q, Shi D-R: Abberant expression of the c-erbB-2/neu protooncogene in ovarian cancer. Cancer Lett 61:95-103, 1992
3. 3. Hynes NE: Amplification and overexpression of the erbB-2 gene in human tumors: Its involvement in tumor development, significance as a prognostic factor, and potential as a target for cancer therapy. Cancer Biol 4:19-26, 1993
4. 4. Drebin JA, Link VC, Stern DF, Weinberg RA, Greene MI: Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies. Cell 41:695-706, 1985
5. 5. Pietras RJ, Fendly BM, Chazin VR, Pegram MD, Howell SB, Slamon DJ: Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene 9:1829-1838, 1994
6. 6. Tagliabue E, Centis F, Campiglio M, Mastroianni A, Martignone S, Pellegrini R, Casalini P, Lanzi C, Menard S, Conalghi MI: Selection of of monoclonal antibodies which induce internalization and phosphorylation of p185HER2 and growth inhibition of cells with HER2/neu gene amplification. Int J Cancer 47:933-937, 1991
7. 7. Kasprzyk PG, Song SU, Fiore PPD, King CR: Therapy of an animal model of human gastric cancer using a combination of anti-erbB-2 monoclonal antibodies. Cancer Res 52:2771-2776, 1992
8. 8. Batra JK, Kasprzyk PG, Bird RE, Pastan I, King CR: Recombinant anti-erbB2 immunotoxins containing pseudonoma exotoxin. Proc Natl Acad Sci USA 89:5867-5871, 1992
9. 9. Bertram J, Killian M, Brysch W, Schlingensiepen K-H, Kneba M: Reduction of erbB2 gene product in mamma carcinoma cell lines by erbB2 mRNA-specific and tyrosine kinase consensus phosphorothiate antisense oligonucleotides. Biochem Biophys Res Commun 200:661-667, 1994
10. 10. Brysch W, Magal E, Louis J-C, Kunst M, Klinger I, Schlingensiepen R, Schlingensiepen K-H: Inhibition of p185c-erbB-2 proto-oncogene expression by antisense oligodeoxynucleotide down-regulates p185-associated tyrosine kinase activity and strongly inhibits mammary tumor-cell proliferation. Cancer Gene Ther 1:99-105, 1994
11. 11. Deshane J, Loechel F, Conry RM, Siegal GP, King CR, Curiel DT: Intracellular single-chain antibody directed against erbB2 down-regulates cell surface erb2 and exhibits a selective anti-proliferative effect in erbB2 overexpressing cancer cell lines. Gene Ther 1:332-337, 1994
12. 12. Deshane J, Grim J, Loechel S, Siegal GP, Alvarez RD, King CR, Curiel DT: Intracellular antibody directed against erbB2 mediates tumor cell eradication by inducing apoptosis. Cancer Gene Ther 3:89-98, 1996
13. 13. Deshane J, Cabrera G, Grim JE, Siegal GP, Pike J, Alvarez RD, Curiel DT: Targeted eradication of ovarian cancer mediated by intracellular expression of anti-erbB-2 single-chain antibody. Gynecol Oncol 59:8-14, 1995
14. 14. Deshane J, Siegal GP, Alvarez RD, Wang M-H, Feng M, Cabrera G, Liu T, Kay M, Curiel DT: Targeted tumor killing via an intracellular antibody against erbB-2. J Clin Invest 96:2980-2989, 1995
15. 15. Grim J, Deshane J, Feng M, Lieber A, Kay M, Curiel DT: ErbB-2 knockout employing an intracellular single chain antibody (sFv) accomplishes specific toxicity in erbB-2 expressing lung cancer cells. Am J Respir Cell Mol Biol (in press)
16. 16. Panoskaltsis-Mortari A, Bucy RP: In situ hybridization with digoxigenin-labeled RNA probes: Facts and artifacts. Biotechniques 18:300-307, 19957
17. 17. CellTiter 96 Non-Radioactive Cell Proliferation Assay Technical Bulletin, TB 169, Promega Corporation
18. 18. Bass C, Cabrera G, Elgavish A, Robert B, Siegal GP, Anderson SC, Maneval DC, Curiel DT: Recombinant adenovirus-mediated gene transfer to genitourinary epithelium in vitro and in vivo. Cancer Gene Ther 2:97-104, 1995
19. 19. Rosenfeld ME, Wang M-H, Siegal GP, Alvarez RD, Mikheeva G, Krasnykh V, Curiel DT: Adenoviral-mediated delivery of herpes simplex virus thymidine kinase results in tumor reduction and prolonged survival in a SCID mouse model of human ovarian carcinoma. J Mol Med (in press)
20. 20. Smythe WR, Kaiser LR, Hwang HC, Amin KM, Pilewski JM, Eck SJ, Wilson JM, Abelda SM: Successful adenovirus-mediated gene transfer in an in vivo model of human malignant mesothelioma. Ann Thorac Surg 57:1395-1401, 1994
21. 21. Vile RG, Nelson JA, Castleden S, Chong H, Hart IR: Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component. Cancer Res 54:6228-6234, 1994
22. 22. Baserga R: Oncogenes and the strategy of growth factors. Cell 79:927-930, 1994
23. 23. Hwang HC, Smythe WR, Elshami AA, Kucharczuk JC, Amin KM, Williams JP, Litzky LA, Kaiser LR, Abelda SM: Gene therapy using adeno virus carrying the herpes simplex-thymidine kinase gene to treat in vivo models of human malignant mesothelioma and lung cancer. Am J Respir Cell Mol Biol 13:7-16, 1995
24. 24. Hayashi Y, DePaoli AM, Burant CF, Refetoff S: Expression of a thyroid hormone-responsive recombinant gene introduced into adult mice livers by replication-defective adenovirus can be regulated by endogenous thyroid hormone receptor. J Biol Chem 269:23872-23875, 1993
25. 25. Maeda H, Danel C, Crystal RG: Adenovirus-mediated transfer of human lipase complementary DNA to the gallbladder. Gastroenterology 106:1638-1644, 1994
26. 26. Stratford-Perricaudet LD, Makeh I, Perricaudet M, Briand P: Wide-spread long-term gene transfer to mouse skeletal muscles and heart. J Clin Invest 90:626-630, 1992
27. 27. Brody SL, Jaffe A, Han SK, Wersto RP, Crystal RG: Direct in vivo gene transfer and expression in malignant cells using adenovirus vectors. Hum Gene Ther 5:437-447, 1994
28. 28. Yee D, McGuire SE, Brunner N, Kozelsky TW, Allred DC, Chen S-H, Woo SLC: Adenovirus-mediated gene transfer of herpes simplex virus thymidine kinase in an ascites model of human breast cancer. Hum Gene Ther 7:1251-1257, 1996
29. 29. Osaki T, Tanio Y, Tachibana I, Hosoe S, Kumagai T, Kawase I, Oikawa S, Kishimoto T: Gene therapy for carcinoembryonic antigen-producing human lung cancer cells by cell type-specific expression of herpes simplex virus thymidine kinase gene. Cancer Res 54:5258-5261, 1994
30. 30. Garver RI, Goldsmith KT, Rodu B, Hu P-C, Sorscher EJ: Strategy for achieving selective killing of carcinomas. Gene Ther 1:46-50, 1994
31. 31. DiMaio JM, Clary BM, Via DF, Coveney E, Pappas TN, Lyerly HK: Directed enzyme pro-drug gene therapy for pancreatic cancer in vivo. Surgery 116:205-213, 1994
32. 32. Manome Y, Abe M, Hagen MF, Fine HA, Kufe DW: Enhancer sequences of the DF3 gene regulate expression of the herpes simplex virus thymidine kinase gene and confer sensitivity of human breast cancer cells to gancyclovir. Cancer Res 54:5408-5413, 1994
33. 33. Ido A, Nakata K, Kato Y, Nakao K, Murata K, Fujita M, Ishii N, Tamaoki T, Shiku H, Nagataki S: Gene therapy for hepatoma cells using a retrovirus vector carrying herpes simplex virus thymidine kinase gene under the control of human α-fetoprotein gene promoter. Cancer Res 55:3105-3109, 1995
34. 34. McPhaul MJ, Deslypere J-P, Allman DR, Gerard RD: The adenovirus-mediated delivery of a reporter gene permits the assessment of androgen receptor function in genital skin fibroblast cultures. J Biol Chem 269:26063-26066, 1993
35. 35. Varley AW, Coulthard MG, Meidell RS, Gerard RD: Inflammation-induced recombinant protein expression in vivo using promoters from acute-phase protein genes. Proc Natl Acad Sci USA 92:5346-5350, 1995
36. 36. Kaneko S, Hallenbeck P, Kotani T, Nakabayashi H, McGarrity G, Tamaoki T, Anderson WF, Chiang YL: Adenovirus-mediated gene therapy of hepatocellular carcinoma using cancer-specific gene expression. Cancer Res 55:5283-5287, 1995
37. 37. Tanaka T, Kanai F, Okabe S, Yoshida Y, Wakimoto H, Hamada H, Shiratori Y, Lan K-H, Ishitobi M, Omata M: Adenovirus-mediated prodrug gene therapy for carcinoembryonic antigen-producing human gastric carcinoma cells in vitro. Cancer Res 56:1341-1345, 1996
38. 38. Chung I, Crystal RG, Deisseroth AB: Development of an adenoviral vector system which confers gene expression which is specific for neoplastic cells. Proc Am Assoc Cancer Res 37:347, 1996
39. 39. Orkin SH, Motulsky AG: National Institutes of Health: Report and recommendations of the panel to assess the NIH investment in research on gene therapy. Fed Reg, in press